Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation

J. Waterman, L. Rybicki, B. Bolwell, E. Copelan, B. Pohlman, J. Sweetenham, R. Dean, R. Sobecks, S. Andresen, M. Kalaycio

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML). We hypothesized that the risk that fludarabine imparts to stem cell mobilization and t-MDS/AML would be affected by dose or timing. All patients with FL treated at Cleveland Clinic from 1991 to 2007 with autologous hematopoietic cell transplantation were evaluated. Recursive partitioning analysis was used to explore associations of fludarabine and mitoxantrone dose and timing with poor stem cell harvest and t-MDS/AML. We identified 171 patients, of whom 52 previously received fludarabine. Patients exposed to fludarabine prior to auto-HCT were more likely to require >5 days of leukapheresis (P<0.001) and second stem cell mobilization (P<0.001), especially at a cumulative dose 150 mg/m 2. Univariable risk factors for t-MDS/AML included the number of chemotherapy regimens before auto-HCT, the need for >5 days of leukapheresis to collect CD34+ cells and fludarabine exposure in a dose-dependent manner, particularly when >500 mg/m 2. A cumulative dose of fludarabine >150 mg/m 2 increases the risk for poor stem cell harvests and any exposure increases the risk of t-MDS/AML, with the greatest risk being at doses >500 mg/m 2.

Original languageEnglish (US)
Pages (from-to)488-493
Number of pages6
JournalBone Marrow Transplantation
Volume47
Issue number4
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Follicular Lymphoma
Cell Transplantation
Stem Cells
Hematopoietic Stem Cell Mobilization
Leukapheresis
Therapeutics
Mitoxantrone
Myelodysplastic Syndromes
fludarabine
Acute Myeloid Leukemia

Keywords

  • acute myelogenous leukemia
  • autologous hematopoietic cell transplantation
  • fludarabine
  • follicular lymphoma
  • myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. / Waterman, J.; Rybicki, L.; Bolwell, B.; Copelan, E.; Pohlman, B.; Sweetenham, J.; Dean, R.; Sobecks, R.; Andresen, S.; Kalaycio, M.

In: Bone Marrow Transplantation, Vol. 47, No. 4, 01.04.2012, p. 488-493.

Research output: Contribution to journalArticle

Waterman, J. ; Rybicki, L. ; Bolwell, B. ; Copelan, E. ; Pohlman, B. ; Sweetenham, J. ; Dean, R. ; Sobecks, R. ; Andresen, S. ; Kalaycio, M. / Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 4. pp. 488-493.
@article{1f8f3c3c4f18483cae32b5a4b98d1ebd,
title = "Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation",
abstract = "Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML). We hypothesized that the risk that fludarabine imparts to stem cell mobilization and t-MDS/AML would be affected by dose or timing. All patients with FL treated at Cleveland Clinic from 1991 to 2007 with autologous hematopoietic cell transplantation were evaluated. Recursive partitioning analysis was used to explore associations of fludarabine and mitoxantrone dose and timing with poor stem cell harvest and t-MDS/AML. We identified 171 patients, of whom 52 previously received fludarabine. Patients exposed to fludarabine prior to auto-HCT were more likely to require >5 days of leukapheresis (P<0.001) and second stem cell mobilization (P<0.001), especially at a cumulative dose 150 mg/m 2. Univariable risk factors for t-MDS/AML included the number of chemotherapy regimens before auto-HCT, the need for >5 days of leukapheresis to collect CD34+ cells and fludarabine exposure in a dose-dependent manner, particularly when >500 mg/m 2. A cumulative dose of fludarabine >150 mg/m 2 increases the risk for poor stem cell harvests and any exposure increases the risk of t-MDS/AML, with the greatest risk being at doses >500 mg/m 2.",
keywords = "acute myelogenous leukemia, autologous hematopoietic cell transplantation, fludarabine, follicular lymphoma, myelodysplastic syndrome",
author = "J. Waterman and L. Rybicki and B. Bolwell and E. Copelan and B. Pohlman and J. Sweetenham and R. Dean and R. Sobecks and S. Andresen and M. Kalaycio",
year = "2012",
month = "4",
day = "1",
doi = "10.1038/bmt.2011.109",
language = "English (US)",
volume = "47",
pages = "488--493",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation

AU - Waterman, J.

AU - Rybicki, L.

AU - Bolwell, B.

AU - Copelan, E.

AU - Pohlman, B.

AU - Sweetenham, J.

AU - Dean, R.

AU - Sobecks, R.

AU - Andresen, S.

AU - Kalaycio, M.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML). We hypothesized that the risk that fludarabine imparts to stem cell mobilization and t-MDS/AML would be affected by dose or timing. All patients with FL treated at Cleveland Clinic from 1991 to 2007 with autologous hematopoietic cell transplantation were evaluated. Recursive partitioning analysis was used to explore associations of fludarabine and mitoxantrone dose and timing with poor stem cell harvest and t-MDS/AML. We identified 171 patients, of whom 52 previously received fludarabine. Patients exposed to fludarabine prior to auto-HCT were more likely to require >5 days of leukapheresis (P<0.001) and second stem cell mobilization (P<0.001), especially at a cumulative dose 150 mg/m 2. Univariable risk factors for t-MDS/AML included the number of chemotherapy regimens before auto-HCT, the need for >5 days of leukapheresis to collect CD34+ cells and fludarabine exposure in a dose-dependent manner, particularly when >500 mg/m 2. A cumulative dose of fludarabine >150 mg/m 2 increases the risk for poor stem cell harvests and any exposure increases the risk of t-MDS/AML, with the greatest risk being at doses >500 mg/m 2.

AB - Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML). We hypothesized that the risk that fludarabine imparts to stem cell mobilization and t-MDS/AML would be affected by dose or timing. All patients with FL treated at Cleveland Clinic from 1991 to 2007 with autologous hematopoietic cell transplantation were evaluated. Recursive partitioning analysis was used to explore associations of fludarabine and mitoxantrone dose and timing with poor stem cell harvest and t-MDS/AML. We identified 171 patients, of whom 52 previously received fludarabine. Patients exposed to fludarabine prior to auto-HCT were more likely to require >5 days of leukapheresis (P<0.001) and second stem cell mobilization (P<0.001), especially at a cumulative dose 150 mg/m 2. Univariable risk factors for t-MDS/AML included the number of chemotherapy regimens before auto-HCT, the need for >5 days of leukapheresis to collect CD34+ cells and fludarabine exposure in a dose-dependent manner, particularly when >500 mg/m 2. A cumulative dose of fludarabine >150 mg/m 2 increases the risk for poor stem cell harvests and any exposure increases the risk of t-MDS/AML, with the greatest risk being at doses >500 mg/m 2.

KW - acute myelogenous leukemia

KW - autologous hematopoietic cell transplantation

KW - fludarabine

KW - follicular lymphoma

KW - myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84859447672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859447672&partnerID=8YFLogxK

U2 - 10.1038/bmt.2011.109

DO - 10.1038/bmt.2011.109

M3 - Article

C2 - 21572461

AN - SCOPUS:84859447672

VL - 47

SP - 488

EP - 493

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -